Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML

Leukemia Research

Volumn 38, Issue 8, 2014, Pages 964-969

  Lichtenegger, Felix S ^a,b   Lorenz, Robin ^a,b   Gellhaus, Katharina ^c   Hiddemann, Wolfgang ^a   Beck, Barbara ^a,b   Subklewe, Marion ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Clinical Co operation Group Immunotherapy at the Helmholtz Institute Munich   (Germany)

^c EPIONTIS GMBH   (Germany)

Author keywords

Acute myeloid leukemia; Cytotoxic therapy; Immunomonitoring; Maintenance therapy; NK cell; T regulatory cell

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TIOGUANINE; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER REGRESSION; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE STATUS; IMMUNOCOMPETENT CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ACUTE MYELOID LEUKEMIA; CYTOTOXIC THERAPY; IMMUNOMONITORING; MAINTENANCE THERAPY; NK CELL; T REGULATORY CELL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL PROLIFERATION; FEMALE; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; REMISSION INDUCTION; T-LYMPHOCYTES, REGULATORY;

EID: 84904542856     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2014.05.014     Document Type: Article

References (28)

1. Burnett A.K. Treatment of acute myeloid leukemia: are we making progress. Hematology Am Soc Hematol Educ Program 2012, 2012:1-6.
2. Ferrara F., Schiffer C.A. Acute myeloid leukaemia in adults. Lancet 2013, 381:484-495.
3. Büchner T., Urbanitz D., Hiddemann W., Rühl H., Ludwig W.D., Fischer J., et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group. J Clin Oncol 1985, 3:1583-1589.
4. Büchner T., Hiddemann W., Berdel W.E., Wörmann B., Schoch C., Fonatsch C., et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 2003, 21:4496-4504.
5. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008, 8:59-73.
6. Bracci L., Schiavoni G., Sistigu A., Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2013, 21:15-25.
7. Pielken H.J., Urbanitz D., Koch P., van de Loo J. Immunological monitoring in remission acute myeloid leukemia during maintenance therapy. Haematol Blood Transfus 1987, 30:385-386.
8. Panoskaltsis N., Reid C.D., Knight S.C. Quantification and cytokine production of circulating lymphoid and myeloid cells in acute myelogenous leukaemia. Leukemia 2003, 17:716-730.
9. Ersvaer E., Liseth K., Skavland J., Gjertsen B.T., Bruserud Ø. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells. BMC Immunol 2010, 11:38-49.
10. Szczepanski M.J., Szajnik M., Czystowska M., Mandapathil M., Strauss L., Welsh A., et al. Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 2009, 15:3325-3332.
11. Kanakry C.G., Hess A.D., Gocke C.D., Thoburn C., Kos F., Meyer C., et al. Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood 2011, 117:608-617.
12. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007, 56:641-648.
13. Greten T.F., Ormandy L.A., Fikuart A., Höchst B., Henschen S., Hörning M., et al. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J Immunother 2010, 33:211-218.
14. Ge Y., Domschke C., Stoiber N., Schott S., Heil J., Rom J., et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome. Cancer Immunol Immunother 2012, 61:353-362.
15. Viaud S., Flament C., Zoubir M., Pautier P., LeCesne A., Ribrag V., et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011, 71:661-665.
16. Wieczorek G., Asemissen A., Model F., Turbachova I., Floess S., Liebenberg V., et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009, 69:599-608.
17. Cooper M.A., Fehniger T.A., Caligiuri M.A. The biology of human natural killer-cell subsets. Trends Immunol 2001, 22:633-640.
18. Lichtenegger F.S., Schnorfeil F.M., Hiddemann W., Subklewe M. Current strategies in immunotherapy for acute myeloid leukemia. Immunotherapy 2013, 5:63-78.
19. Walter S., Weinschenk T., Stenzl A., Zdrojowy R., Pluzanska A., Szczylik C., et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012, 18:1254-1261.
20. Chu C.S., Boyer J., Schullery D.S., Gimotty P.A., Gamerman V., Bender J., et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012, 61:629-641.
21. Lion E., Willemen Y., Berneman Z.N., Van Tendeloo V.F., Smits E.L. Natural killer cell immune escape in acute myeloid leukemia. Leukemia 2012, 26:2019-2026.
22. Piloto O., Levis M., Huso D., Li Y., Li H., Wang M.N., et al. Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2005, 65:1514-1522.
23. Korver W., Zhao X., Singh S., Pardoux C., Zhao J., Guzman M.L., et al. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. Leukemia 2009, 23:1587-1597.
24. Hofmann M., Große-Hovest L., Nübling T., Pyz E., Bamberg M.L., Aulwurm S., et al. Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia. Leukemia 2012, 26:1228-1237.
25. Mohseni Nodehi S., Repp R., Kellner C., Bräutigam J., Staudinger M., Schub N., et al. Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96. PLoS ONE 2012, 7:e42426.
26. Askmyr M., Ågerstam H., Hansen N., Gordon S., Arvanitakis A., Rissler M., et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 2013, 121:3709-3713.
27. Romero A.I., Thorén F.B., Aurelius J., Askarieh G., Brune M., Hellstrand K. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML. Scand J Immunol 2009, 70:194-205.
28. Schmiedel B.J., Werner A., Steinbacher J., Nuebling T., Buechele C., Grosse-Hovest L., et al. Generation and preclinical characterization of a Fc-optimized GITR-Ig fusion protein for induction of NK cell reactivity against leukemia. Mol Ther 2013, 21:877-886.